Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 7/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | MET | P08581 | 5/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9103980 | 1.00 | HCRTR1 (0.44) | HCRTR1HTR1AADRA1ADRD2MET | |
| SCHEMBL9103413 | 0.93 | HCRTR1 (0.44) | HCRTR1METHCRTR2NAMPTGRM5 | |
| SCHEMBL9103418 | 0.93 | HCRTR1 (0.44) | HCRTR1METHCRTR2NAMPTGRM5 | |
| SCHEMBL9281079 | 0.89 | HTR7 (0.43) | HCRTR1METHCRTR2NAMPT | |
| SCHEMBL9281080 | 0.89 | HTR7 (0.43) | HCRTR1METHCRTR2NAMPT | |
| SCHEMBL9102305 | 0.88 | HCRTR1 (0.43) | HCRTR1METHCRTR2NAMPT | |
| SCHEMBL9102309 | 0.88 | HCRTR1 (0.43) | HCRTR1METHCRTR2NAMPT | |
| SCHEMBL9105328 | 0.86 | P2RX7 (0.42) | HCRTR1METHCRTR2 | |
| SCHEMBL9105324 | 0.86 | P2RX7 (0.42) | HCRTR1METHCRTR2 | |
| SCHEMBL1241492 | 0.83 | HCRTR1 (0.40) | HCRTR1METHCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969383-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8809380-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | HCRTR1 471/4885HTR1A 1258/4885ADRA1A 2300/4885 |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | HCRTR1 471/4885HTR1A 1258/4885ADRA1A 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.